drugset / Trial / NCT02186119

A Study of Abicipar Pegol in Patients With Diabetic Macular Edema

NCT02186119

Phase 2 Completed 151 enrolled Allergan
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a safety and efficacy study of abicipar pegol in patients with diabetic macular edema.

Timeline

Start
2014-07
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Abicipar pegol Protein / enzyme biologic 1 mg Intravitreal
Subject Abicipar pegol Protein / enzyme biologic 2 mg Intravitreal
Comparator Ranibizumab Monoclonal antibody Intravitreal

Indications